baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

vTv Therapeutics/ US9183852048 /

5/16/2024 9:59:41 PM	Chg. +1.43	Volume	Bid-	Ask-	High	Low
27.09USD	+5.55%	14 Turnover: 374.06	-Bid Size: -	-Ask Size: -	27.09	26.57

GlobeNewswire 5/9 vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

GlobeNewswire 3/13 vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporat...

GlobeNewswire 3/4 vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with ...

GlobeNewswire 3/1 vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

GlobeNewswire 2/28 vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Inves...

GlobeNewswire 2/21 AdhereTech Announces Appointment of Paul Sekhri to Board of Directors

GlobeNewswire 11/13/2023 Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

GlobeNewswire 11/9/2023 vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire 11/8/2023 vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

GlobeNewswire 11/2/2023 vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

GlobeNewswire 11/1/2023 vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

GlobeNewswire 3/23/2022 Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Busin...

GlobeNewswire 1/13/2022 vTv Therapeutics Shares Updated Corporate Presentation

GlobeNewswire 12/6/2021 vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations

GlobeNewswire 11/9/2021 vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire 10/12/2021 vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of K...

GlobeNewswire 10/6/2021 Lottery.com Announces Nominees to the Post-Closing Board of Directors

GlobeNewswire 9/23/2021 vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737,...

GlobeNewswire 8/4/2021 vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire 6/29/2021 vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Pos...

GlobeNewswire 6/22/2021 vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development a...

GlobeNewswire 5/5/2021 vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update

GlobeNewswire 4/13/2021 vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type ...

GlobeNewswire 4/12/2021 TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100...

GlobeNewswire 3/23/2021 vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399

vTv Therapeutics/ US9183852048 /

If you wish to receive reply to your feedback, please provide your email address.